Plasmodium falciparum — Drug Target

All drugs that target Plasmodium falciparum — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Antimalarial

Marketed (1)

• RIAMET (artemether + LUMEFANTRIN combination) · Assistance Publique - Hôpitaux de Paris · Antimalarial · Metabolic
  Riamet combines artemether, a fast-acting antimalarial, with lumefantrine, a longer-acting partner, to provide a synergistic effect against Plasmodium falciparum.

Phase 3 pipeline (2)

• sulfadoxine-pyrimethamine / mefloquine · Institut de Recherche pour le Developpement · Antimalarial · Infectious Diseases
  Sulfadoxine-pyrimethamine is a combination of a sulfonamide antibiotic and a dihydrofolate reductase inhibitor, while mefloquine is a blood schizonticide.
• artesunate-sulphadoxin/pyrimethamine, chloroquine · University of Oxford · Antimalarial · Infectious Diseases
  Artesunate-sulphadoxin/pyrimethamine works by inhibiting the growth of malaria parasites, while chloroquine targets the parasite's digestive enzyme.

Phase 2 pipeline (1)

• Artefenomel-Ferroquine · Centre de Recherche Médicale de Lambaréné · Antimalarial · Infectious Diseases
  Artefenomel-Ferroquine is a combination of artefenomel and ferroquine, which targets the Plasmodium falciparum parasite.